Rapid clonal expansion and prolonged maintenance of memory CD8+ T cells of the effector (CD44highCD62Llow) and central (CD44highCD62Lhigh) phenotype by an archaeosome adjuvant independent of TLR2

Journal of Immunology

Volumn 178, Issue 4, 2007, Pages 2396-2406

  Krishnan, Lakshmi ^a,b   Gurnani, Komal ^a   Dicaire, Chantal J ^a   Van Faassen, Henk ^a   Zafer, Ahmed ^a   Kirschning, Carsten J ^b,c   Sad, Subash ^a,b   Sprott, G Dennis ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; GLYCEROLIPID; HERMES ANTIGEN; INTERLEUKIN 7 RECEPTOR ALPHA; L SELECTIN; OVALBUMIN; TOLL LIKE RECEPTOR 2;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CELL CYCLE; CELLULAR IMMUNITY; CLONAL ANERGY; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; IMMUNIZATION; IMMUNOLOGICAL MEMORY; LIPID VESICLE; LISTERIA MONOCYTOGENES; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; METHANOBREVIBACTER SMITHII; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 33846934177     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.4.2396     Document Type: Article

References (58)

1. Pulendran, B., K. Palucka, and J. Banchereau. 2001. Sensing pathogens and tuning immune responses. Science 293: 253-256.
2. Zinkernagel, R. M., and P. C. Doherty. 1997. The discovery of MHC restriction. Immunol. Today 18: 14-17.
3. Sant, A., and J. Yewdell. 2003. Antigen processing and recognition. Curr. Opin. Immunol. 15: 66-68.
4. Henkart, P. A. 1994. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1: 343-346.
5. Kaech, S. M., E. J. Wherry, and R. Ahmed. 2002. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2: 251-262.
6. Sad, S., and L. Krishnan. 2003. Maintenance and attrition of T-cell memory. Crit. Rev. Immunol. 23: 129-147.
7. Selin, L. K., K. Vergilis, R. M. Welsh, and S. R. Nahill. 1996. Reduction of otherwise remarkably stable virus-specific cytotoxic T lymphocyte memory by heterologous viral infections. J. Exp. Med. 183: 2489-2499.
8. Wherry, E. J., V. Teichgraber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. von Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4: 225-234.
9. O'Hagan, D. T., and N. M. Valiante. 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2: 727-735.
10. Gupta, R. K., B. E. Rost, R. E. Reyveld, and G. S. Siber. 1995. Adjuvant properties of aluminum and calcium compounds. In Vaccine Design: The Subunit and Adjuvant Approach. M. F. Powell and M. J. Newman, eds. Plenum Press, New York, pp. 229-248.
11. Hunter, R. L. 2002. Overview of vaccine adjuvants: present and future. Vaccine 20(Suppl. 3): S7-S12.
12. Roland, K. L., S. A. Tinge, K. P. Killeen, and S. K. Kochi. 2005. Recent advances in the development of live, attenuated bacterial vectors. Curr. Opin. Mol. Ther. 7: 62-72.
13. Belz, G. T., F. R. Carbone, and W. R. Heath. 2002. Cross-presentation of antigens by dendritic cells. Crit. Rev. Immunol. 22: 439-448.
14. Kaisho, T., and S. Akira. 2002. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta 1589: 1-13.
15. Kates, M. 1992. Archaebacterial lipids:structure, biosynthesis and function. Biochem. Soc. Symp. 58: 51-72.
16. Sprott, G. D. 1992. Structures of archaeobacterial membrane lipids. J. Bioenerg. Biomembr. 24: 555-566.
17. Sprott, G. D., G. B. Patel, and L. Krishnan. 2003. Archaeobacterial ether lipid liposomes as vaccine adjuvants. Methods Enzymol. 373: 155-172.
18. Sprott, G. D., J. Brisson, C. J. Dicaire, A. K. Pelletier, L. A. Deschatelets, L. Krishnan, and G. B. Patel. 1999. A structural comparison of the total polar lipids from the human archaea Methanobrevibacter smithii and Methanosphaera stadtmanae and its relevance to the adjuvant activities of their liposomes. Biochim. Biophys. Acta 1440: 275-288.
19. Gurnani, K., J. Kennedy, S. Sad, G. D. Sprott, and L. Krishnan. 2004. Phosphatidylserine receptor-mediated recognition of archaeosome adjuvant promotes endocytosis and MHC class 1 cross-presentation of the entrapped antigen by phagosome-to-cytosol transport and classical processing. J. Immunol. 173: 566-578.
20. Sprott, G. D., S. Sad, L. P. Fleming, C. Dicaire, G. B. Patel, and L. Krishnan. 2003. Archaeosomes varying in lipid composition differ in receptor-mediated endocytosis and differentially adjuvant immune responses to entrapped antigen. Archaea 1: 151-164.
21. + T cell help. J. Immunol. 165: 5177-5185.
22. Krishnan, L., S. Sad, G. B. Patel, and G. D. Sprott. 2001. The potent adjuvant activity of archaeosomes correlates to the recruitment and activation of macrophages and dendritic cells in vivo. J. Immunol. 166: 1885-1893.
23. Krishnan, L., S. Sad, G. B. Patel, and G. D. Sprott. 2003. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Cancer Res. 63: 2526-2534.
24. Krishnan, L., and S. G. Dennis. 2003. Archaeosomes as self-adjuvanting delivery systems for cancer vaccines. J. Drug Target 11: 515-524.
25. Conlan, J. W., L. Krishnan, G. B. Patel, and G. D. Sprott. 2001. Immunization of mice with lipopeptide antigens encapsulated in specialized liposomes prepared from the total polar lipids of various archaeobacteria elicits rapid prolonged protective immunity against the facultative intracellular pathogen Listeria monocytogenes. Vaccine 19: 3509-3517.
26. Wooten, R. M., Y. Ma, R. A. Yoder, J. P. Brown, J. H. Weis, J. F. Zachary, C. J. Kirschning, and J. J. Weis. 2002. Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi. J. Immunol. 168: 348-355.
27. + T cell priming initially: comparison between an acute versus a chronic intracellular bacterium expressing a model antigen. J. Immunol. 168: 5737-5745.
28. Moore, M. W., F. R. Carbone, and M. J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54: 777-785.
29. Barber, D. L., E. J. Wherry, and R. Ahmed. 2003. Cutting edge: rapid in vivo killing by memory CD8 T cells. J. Immunol. 171: 27-31.
30. Rotzschke, O., K. Falk, S. Stevanovic, G. Jung, P. Walden, and H. G. Rammensee. 1991. Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21: 2891.
31. Evans, J. T., C. W. Cluff, D. A. Johnson, M. J. Lacy, D. H. Persing, and J. R. Baldridge. 2003. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi. 529. Expert Rev. Vaccines 2: 219-229.
32. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124: 783-801.
33. Krishnan, L., C. J. Dicaire, G. B. Patel, and G. D. Sprott. 2000. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated and memory responses: comparison to conventional liposomes and alum. Infect. Immun. 68: 54-63.
34. + T cells to apoptosis in vivo. J. Immunol. 169: 3760-3770.
35. + T cells undergoing primary and secondary responses to infection in the same host. J. Immunol. 170: 4933-4942.
36. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
37. Kaech, S. M., J. T. Tan, E. J. Wherry, B. T. Konieczny, C. D. Surh, and R. Ahmed. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4: 1191-1198.
38. Cerwenka, A., T. M. Morgan, and R. W. Dutton. 1999. Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. J. Immunol. 163: 5535-5543.
39. Masopust, D., V. Vezys, A. L. Marzo, and L. Lefrancois. 2001. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291: 2413-2417.
40. + T cells. J. Exp. Med. 194: 1711-1719.
41. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8: 379-385.
42. Champagne, P., G. S. Ogg, A. S. King, C. Knabenhans, K. Ellefsen, M. Nobile, V. Appay, G. P. Rizzardi, S. Fleury, M. Lipp, et al. 2001. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410: 106-111.
43. Beveridge, T. J., C. G. Choquet, G. B. Patel, and G. D. Sprott. 1993. Freeze-fracture planes of methanogen membranes correlate with the content of tetraether lipids. J. Bacteriol. 175: 1191-1197.
44. + T cell turnover during mycobacterial infection: comparison with Listeria monocytogenes. J. Immunol. 172: 3491-3500.
45. Moskophidis, D., F. Lechner, H. Pircher, and R. M. Zinkernagel. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362: 758-761.
46. Zajac, A. J., J. N. Blattman, K. K. Murali, D. J. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188: 2205-2213.
47. Pulendran, B., and R. Ahmed. 2006. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124: 849-863.
48. Quesniaux, V., C. Fremond, M. Jacobs, S. Parida, D. Nicolle, V. Yeremeev, F. Bihl, F. Erard, T. Botha, M. Drennan, et al. 2004. Toll-like receptor pathways in the immune responses to mycobacteria. Microbes Infect. 6: 946-959.
49. Schroder, N. W., S. Morath, C. Alexander, L. Hamann, T. Hartung, U. Zahringer, U. B. Gobel, J. R. Weber, and R. R. Schumann. 2003. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide- binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J. Biol. Chem. 278: 15587-15594.
50. Massari, P., P. Henneke, Y. Ho, E. Latz, D. T. Golenbock, and L. M. Wetzler. 2002. Cutting edge: immune stimulation by neisserial porins is Toll-like receptor 2 and MyD88 dependent. J. Immunol. 168: 1533-1537.
51. Lepp, P. W., M. M. Brinig, C. C. Ouverney, K. Palm, G. C. Armitage, and D. A. Relman. 2004. Methanogenic archaea and human periodontal disease. Proc. Natl. Acad. Sci. USA 101: 6176-6181.
52. Robinson, H. L., and R. R. Amara. 2005. T cell vaccines for microbial infections. Nat. Med. 11: S25-S32.
53. Rousset, D., M. Rakoto-Andrianarivelo, R. Razafindratsimandresy, B. Randriamanalina, S. Guillot, J. Balanant, P. Mauclere, and F. Delpeyroux. 2003. Recombinant vaccine-derived poliovirus in Madagascar. Emerg. Infect. Dis. 9: 885-887.
54. Donnelly, J., K. Berry, and J. B. Ulmer. 2003. Technical and regulatory hurdles for DNA vaccines. Int. J. Parasitol. 33: 457-467.
55. Harokopakis, E., N. K. Childers, S. M. Michalek, S. S. Zhang, and M. Tomasi. 1995. Conjugation of cholera toxin or its B subunit to liposomes for targeted delivery of antigens. J. Immunol. Methods 185: 31-42.
56. Verma, J. N., M. Rao, S. Amselem, U. Krzych, C. R. Alving, S. J. Green, and N. M. Wassef. 1992. Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages. Infect. Immun. 60: 2438-2444.
57. Ramshaw, I. A., and A. J. Ramsay. 2000. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 21: 163-165.
58. Medina, E., and C. A. Guzman. 2001. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 19: 1573-1580.